N-BOC--氰基-4-哌啶酮 | 914988-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-BOC--氰基-4-哌啶酮
• 中文别名: N-BOC-氰基-4-哌啶酮；1-Boc-3-氰基-4-哌啶酮；N-Boc-3-氰基-4-哌啶酮；3-氰基-4-氧代-1-哌啶羧酸-1,1-二甲基乙酯
• 英文名称: tert-butyl 3-cyano-4-oxopiperidine-1-carboxylate
• CAS: 914988-10-6
• 化学式: C₁₁H₁₆N₂O₃
• 分子量: 224.26
• InChiKey: VPFTZTMJPFIRAN-UHFFFAOYSA-N

物化性质

• 熔点：
  97-99 °C
• 沸点：
  375.1±42.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  70.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Cyano-4-oxo-piperidine-1-carboxylic acid tert-butyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Cyano-4-oxo-piperidine-1-carboxylic acid tert-butyl ester
CAS number: 914988-10-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H16N2O3
Molecular weight: 224.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-BOC--氰基-4-哌啶酮 在 potassium phosphate 、 copper(l) iodide 、 (1R,2R)-1,2-diaminocyclohexane 、 caesium carbonate 、 一水合肼 、 三氟乙酸 、 copper(ll) bromide 、 亚硝酸异戊酯 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 28.5h， 生成 1-(3-(6-chloro-2-methyl-5-(1-methyl-1H-pyrazol-4-yl)-1H-indol-1-yl)-1-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethanone
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER
  [FR] DÉRIVÉS DE PYRAZOLOPYRIDINE POUR LE TRAITEMENT DU CANCER

  摘要：

  本发明涉及一种化合物公式（I）及其盐，其中R1、R2X和Y具有本文中定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含公式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的疾病，如癌症、炎症性疾病和自身免疫疾病中使用这些化合物和盐的方法。

  公开号：

  WO2017205538A1
• 作为产物：
  描述：

  ethyl 3-((tert-butoxycarbonyl)(2-cyanoethyl)amino)propanoate 在 sodium hydride 作用下， 以 甲苯 、 mineral oil 为溶剂， 反应 1.5h， 以224.2 g的产率得到N-BOC--氰基-4-哌啶酮
  参考文献：
  名称：

  Synthesis and In Vitro Antibacterial Activity of 7-(3-Amino-6,7-dihydro-2-methyl-2H-pyrazolo[4,3-c] Pyridin-5(4H)-yl)fluoroquinolone Derivatives

  摘要：

  本研究设计、合成了一系列新型 7-(3-氨基-6,7-二氢-2-甲基-2H-吡唑并[4,3-c]吡啶-5(4H)-基)氟喹诺酮衍生物，并通过 1H-NMR、MS 和 HRMS 对其进行了表征。对这些氟喹诺酮类药物针对代表性革兰氏阳性和革兰氏阴性菌株的体外抗菌活性进行了评估。结果表明，大多数目标化合物对耐甲氧西林表皮葡萄球菌（MRSE）（MIC：0.25-4 μg/mL）和肺炎链球菌（MIC：0.25-1 μg/mL）具有良好的生长抑制作用。此外，化合物 8f 对耐甲氧西林金黄色葡萄球菌 10-05 和溶血性链球菌 1002 的活性比参考药物吉西沙星（GM）、莫西沙星（MX）、环丙沙星（CP）和左氧氟沙星（LV）高 8-128 倍，对甲氧西林敏感的金黄色葡萄球菌 10-03 和 10-04 的活性高 2-64 倍。

  DOI：

  10.3390/molecules16032626

文献信息

• PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
  申请人：CHEMOCENTRYX, INC.

  公开号：US20190300526A1

  公开（公告）日：2019-10-03

  The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

  本公开提供了化合物IA、IB、IC、IIA、IIB和IIC的结构，或其在药学上可接受的盐，这些化合物是C5a受体的调节剂。还提供了包括治疗涉及C5a病理性激活的疾病或疾病的药物组合物和使用方法，以及非药物应用。
• Synthesis, in Vitro Antimycobacterial and Antibacterial Evaluation of IMB-070593 Derivatives Containing a Substituted Benzyloxime Moiety
  作者：Zengquan Wei、Jian Wang、Mingliang Liu、Sujie Li、Lanying Sun、Huiyuan Guo、Bin Wang、Yu Lu

  DOI：10.3390/molecules18043872

  日期：——

  A series of novel IMB-070593 derivatives containing a substituted benzyloxime moiety and displaying a remarkable improvement in lipophilicity were synthesized and evaluated for their in vitro antimycobacterial and antibacterial activity. Our results reveal that the target compounds 19a–m have considerable Gram-positive activity (MIC: <0.008–32 µg/mL), although they are generally less active than the reference drugs against the Gram-negative strains. In particular, compounds 19h, 19j, 19k and 19m show good activity (MICs: <0.008–4 µg/mL) against all of the tested Gram-positive strains, including ciprofloxacin (CPFX)- and/or levofloxacin (LVFX)-resistant MSSA, MRSA and MSSE. Moreover, compound 19l (MIC: 0.125 µg/mL) is found to be 2–4 fold more active than the parent IMB070593, CPFX and LVFX against M. tuberculosis H37Rv ATCC 27294.

  合成并评价了一系列含有取代苯甲酰肟基团且脂溶性显著提高的新型IMB-070593衍生物的体外抗分枝杆菌和抗菌活性。我们的结果显示，目标化合物19a–m对革兰氏阳性菌具有相当高的活性（MIC：<0.008–32 µg/mL），尽管它们对革兰氏阴性菌的活性通常低于参考药物。特别是化合物19h、19j、19k和19m对所有测试的革兰氏阳性菌株显示出良好的活性（MICs：<0.008–4 µg/mL），包括对环丙沙星（CPFX）和/或左氧氟沙星（LVFX）耐药的甲氧西林敏感金黄色葡萄球菌（MSSA）、甲氧西林耐药金黄色葡萄球菌（MRSA）和表皮葡萄球菌（MSSE）。此外，化合物19l（MIC：0.125 µg/mL）对抗ATCC 27294的结核杆菌H37Rv的活性是母体化合物IMB070593、环丙沙星和左氧氟沙星的2–4倍。
• [EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
  申请人：ABBVIE INC

  公开号：WO2014139328A1

  公开（公告）日：2014-09-18

  Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

  公开的是Formula (IIa)的化合物，其中R1、R2、R3A、R3B、R3C、R3D、R3E和R4如规范中所定义，并且其药用盐。这些化合物可用作治疗疾病，包括癌症的药物。还提供了包含一个或多个Formula (IIa)化合物的药物组合物。
• [EN] 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA 3-PHOSPHOGLYCÉRATE DÉSHYDROGÉNASE ET LEURS UTILISATIONS
  申请人：RAZE THERAPEUTICS INC

  公开号：WO2017156177A1

  公开（公告）日：2017-09-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B<br/>[FR] NOUVEAUX COMPOSÉS DE DIHYDROISOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE L'HÉPATITE B
  申请人：NOVARTIS AG

  公开号：WO2019097479A1

  公开（公告）日：2019-05-23

  PAT057954-WO-PCT ABSTRACT The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

  本发明提供了如下所述的化合物的公式（I）n R3b Z W Q R3a H Y N R1 R4 R2 O（I），以及立体异构体形式、盐、水合物、溶剂合物及其盐以及含有这些化合物的药物组合物和药物组合物，以及使用这些化合物、盐和组合物治疗病毒感染的方法，特别是由乙型肝炎病毒（HBV）引起的感染，并减少与HBV相关的严重病症的发生。